Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Receivables (2018 - 2025)

Arcturus Therapeutics Holdings' Receivables history spans 8 years, with the latest figure at $9.2 million for Q4 2025.

  • For Q4 2025, Receivables rose 41.62% year-over-year to $9.2 million; the TTM value through Dec 2025 reached $9.2 million, up 41.62%, while the annual FY2025 figure was $9.2 million, 41.62% up from the prior year.
  • Receivables reached $9.2 million in Q4 2025 per ARCT's latest filing, down from $15.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $185.0 million in Q1 2023 to a low of $4.0 million in Q1 2021.
  • Average Receivables over 5 years is $31.5 million, with a median of $8.3 million recorded in 2022.
  • Peak YoY movement for Receivables: surged 2405.64% in 2023, then crashed 89.9% in 2024.
  • A 5-year view of Receivables shows it stood at $6.7 million in 2021, then fell by 17.91% to $5.5 million in 2022, then skyrocketed by 1060.06% to $64.1 million in 2023, then plummeted by 89.9% to $6.5 million in 2024, then skyrocketed by 41.62% to $9.2 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Receivables are $9.2 million (Q4 2025), $15.9 million (Q3 2025), and $34.4 million (Q2 2025).